KORU Medical Systems Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of fair value of the stock options granted Black-Scholes option valuation model

The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued:

	September 30,
	2018		2017

Dividend yield		0.00%		0.00%
Expected Volatility		62.8 - 65.2%		70.1 - 72.20%
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		5 Years		5 Years
Risk-free rate		2.80 - 2.90%		2.30 - 2.48%

Schedule of stock option plan

The following table summarizes the status of the Plan:

	Nine months Ended September 30,
	2018			2017
	Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price

Outstanding at January 1	1,038,000	$	0.41		905,000	$	0.37
Granted	1,018,000	$	1.23		568,000	$	0.41
Exercised	125,000	$	0.41		—	$	—
Forfeited	12,000	$	0.87		310,000	$	0.36
Outstanding at September 30	1,919,000	$	0.85		1,163,000	$	0.40
Options exercisable at September 30	666,969	$	0.40		573,000	$	0.38
Stock-based compensation expense	—	$	51,592		—	$	(13,979	)

Schedule of information pertaining to options outstanding

The following table presents information pertaining to options outstanding at September 30, 2018:

Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$0.36 - $1.33	1,919,000	5 years	$	0.85	666,969	$	0.40